> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Lilly’s Tauvid
- URL: https://www.fdaweb.com/regulatory-review-period-for-lillys-tauvid/
- Published: 2022-07-22T12:00:00.000Z
- Updated: 2026-09-14T17:53:01.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152339

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Eli Lilly’s Tauvid (flortaucipir F–18), indicated for positron emission tomography imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease. The review period is 3,067 days, of which 2,825 days occurred during the testing phase and 242 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-07-22/pdf/2022-15679.pdf?ref=fdaweb.com).